View Item 

Show simple item record

Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity

dc.contributor.authorDyck, Peter J.en_US
dc.contributor.authorAlbers, James W.en_US
dc.contributor.authorAndersen, Henningen_US
dc.contributor.authorArezzo, Joseph C.en_US
dc.contributor.authorBiessels, Geert‐janen_US
dc.contributor.authorBril, Veraen_US
dc.contributor.authorFeldman, Eva L.en_US
dc.contributor.authorLitchy, William J.en_US
dc.contributor.authorO'Brien, Peter C.en_US
dc.contributor.authorRussell, James W.en_US
dc.date.accessioned2011-11-10T15:38:17Z
dc.date.available2012-12-03T21:17:30Zen_US
dc.date.issued2011-10en_US
dc.identifier.citationDyck, Peter J.; Albers, James W.; Andersen, Henning; Arezzo, Joseph C.; Biessels, Geert‐jan ; Bril, Vera; Feldman, Eva L.; Litchy, William J.; O'Brien, Peter C.; Russell, James W. (2011). "Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity." Diabetes/Metabolism Research and Reviews 27(7): 620-628. <http://hdl.handle.net/2027.42/87100>en_US
dc.identifier.issn1520-7552en_US
dc.identifier.issn1520-7560en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/87100
dc.description.abstractPrior to a joint meeting of the Neurodiab Association and International Symposium on Diabetic Neuropathy held in Toronto, Ontario, Canada, 13‐18 October 2009, Solomon Tesfaye, Sheffield, UK, convened a panel of neuromuscular experts to provide an update on polyneuropathies associated with diabetes (Toronto Consensus Panels on DPNs, 2009). Herein, we provide definitions of typical and atypical diabetic polyneuropathies (DPNs), diagnostic criteria, and approaches to diagnose sensorimotor polyneuropathy as well as to estimate severity. Diabetic sensorimotor polyneuropathy (DSPN), or typical DPN, usually develops on long‐standing hyperglycaemia, consequent metabolic derangements and microvessel alterations. It is frequently associated with microvessel retinal and kidney disease—but other causes must be excluded. By contrast, atypical DPNs are intercurrent painful and autonomic small‐fibre polyneuropathies. Recognizing that there is a need to detect and estimate severity of DSPN validly and reproducibly, we define subclinical DSPN using nerve conduction criteria and define possible, probable, and confirmed clinical levels of DSPN. For conduct of epidemiologic surveys and randomized controlled trials, it is necessary to pre‐specify which attributes of nerve conduction are to be used, the criterion for diagnosis, reference values, correction for applicable variables, and the specific criterion for DSPN. Herein, we provide the performance characteristics of several criteria for the diagnosis of sensorimotor polyneuropathy in healthy subject‐ and diabetic subject cohorts. Also outlined here are staged and continuous approaches to estimate severity of DSPN. Copyright © 2011 John Wiley & Sons, Ltd.en_US
dc.publisherJohn Wiley & Sons, Ltd.en_US
dc.subject.otherDiabetic Polyneuropathyen_US
dc.subject.otherDiabetic Sensorimotor Polyneuropathyen_US
dc.subject.otherAtypical Diabetic Polyneuropathyen_US
dc.subject.otherClassificationen_US
dc.subject.otherDefinitionsen_US
dc.titleDiabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severityen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Neurology, University of Michigan, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherDepartment of Neurology, Mayo Clinic, Rochester, MN, USAen_US
dc.contributor.affiliationotherAarhus University Hospital, Aarhus, Denmarken_US
dc.contributor.affiliationotherDepartment of Neuroscience, Albert Einstein College of Medicine, New York, NY, USAen_US
dc.contributor.affiliationotherRudolf Magnus Institute, Utrecht, Netherlandsen_US
dc.contributor.affiliationotherDepartment of Medicine, University of Toronto, Toronto, Ontario, Canadaen_US
dc.contributor.affiliationotherDivision of Biostatistics, Mayo Clinic, Rochester, MN, USAen_US
dc.contributor.affiliationotherDepartment of Neurology, University of Maryland, Baltimore, MD, USAen_US
dc.contributor.affiliationotherDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/87100/1/1226_ftp.pdf
dc.identifier.doi10.1002/dmrr.1226en_US
dc.identifier.sourceDiabetes/Metabolism Research and Reviewsen_US
dc.identifier.citedreferenceTesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria and estimation of severity (The Toronto Expert Group Meeting 2009). Diabetes Care 2010; 33 ( 10 ): 2285 – 2293.en_US
dc.identifier.citedreferenceLeyden E. Beitrag zur Klinik des diabetes mellitus. Wien Med Wochenschr 1893; 43: 926.en_US
dc.identifier.citedreferenceDyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population‐based cohort: The Rochester Diabetic Neuropathy Study. Neurology 1993; 43 ( 4 ): 817 – 824.en_US
dc.identifier.citedreferenceLlewelyn JG, Tomlinson DR, Thomas PK. Diabetic neuropathies. In Peripheral Neuropathy ( 4th edn ), Dyck PJ, Thomas PK (eds). Elsevier: Philadelphia, PA, 2005; 1951 – 1992.en_US
dc.identifier.citedreferenceThomas PK. Classification, differential diagnosis and staging of diabetic peripheral neuropathy. Diabetes 1997; 46 ( Suppl. 2 ): S54 – S57.en_US
dc.identifier.citedreferenceThomas PK. Classification of the diabetic neuropathies. In Textbook of Diabetic Neuropathy, Arnold Gries G, Cameron NE, Low PA, Ziegler D (eds). Thieme: Stuttgart, 2003; 175 – 177.en_US
dc.identifier.citedreferenceBoulton AJM, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004; 27 ( 6 ): 1458 – 1486.en_US
dc.identifier.citedreferenceBoulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28 ( 4 ): 956 – 962.en_US
dc.identifier.citedreferenceDyck PJB, Norell JE, Dyck PJ. Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology 1999; 53: 2113 – 2121.en_US
dc.identifier.citedreferenceDyck PJB, Norell JE, Dyck PJ. Non‐diabetic lumbosacral radiculoplexus neuropathy. Natural history, outcome and comparison with the diabetic variety. Brain 2001; 124: 1197 – 1207.en_US
dc.identifier.citedreferenceDCCT Research Group. The Diabetes Control and Complications Trial (DCCT): design and methodologic considerations for the feasibility phase. Diabetes 1986; 35: 530 – 545.en_US
dc.identifier.citedreferenceDCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. N Engl J Med 1993; 329: 977 – 986.en_US
dc.identifier.citedreferenceFeldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two‐step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994; 17 ( 11 ): 1281 – 1289.en_US
dc.identifier.citedreferenceDyck PJ, Davies JL, Wilson DM, Service FJ, Melton LJ, O'Brien PC. Risk factors for severity of diabetic polyneuropathy. Intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care 1999; 22 ( 9 ): 1479 – 1486.en_US
dc.identifier.citedreferenceTesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352: 341 – 350.en_US
dc.identifier.citedreferenceDyck PJ, Davies JL, Clark VM, et al. Modeling chronic glycemic exposure variables as correlates and predictors of microvascular complications of diabetes. Diabetes Care 2006; 29: 2282 – 2288.en_US
dc.identifier.citedreferenceZochodne DW. Diabetic polyneuropathy: an update. Curr Opin Neurol 2008; 21: 527 – 533.en_US
dc.identifier.citedreferenceTomlinson DR. Future prevention and treatment of diabetic neuropathy. Diabetes Metab 1998; 24 ( Suppl. 3 ): 79 – 83.en_US
dc.identifier.citedreferenceOates PJ. Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets 2008; 9: 14 – 36.en_US
dc.identifier.citedreferenceVincent AM, Hinder LM, Pop‐Busui R, Feldman EL. Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J Peripher Nerv Syst 2009; 14: 257 – 267.en_US
dc.identifier.citedreferenceYasuda H, Dyck PJ. Abnormalities of endoneurial microvessels and sural nerve pathology in diabetic neuropathy. Neurology 1987; 37: 20 – 28.en_US
dc.identifier.citedreferenceGiannini C, Dyck PJ. Ultrastructural morphometric features of human sural nerve endoneurial microvessels. J Neuropathol Exp Neurol 1993; 52: 361 – 369.en_US
dc.identifier.citedreferenceGiannini C, Dyck PJ. Ultrastructural morphometric abnormalities of sural nerve endoneurial microvessels in diabetes mellitus. Ann Neurol 1994; 36 ( 3 ): 408 – 415.en_US
dc.identifier.citedreferenceService FJ, Rizza RA, Daube JR, O'Brien PC, Dyck PJ. Near normoglycaemia improved nerve conduction and vibration sensation in diabetic neuropathy. Diabetologia 1985; 28: 722 – 727.en_US
dc.identifier.citedreferenceAmthor K‐F, Dahl‐Jorgensen K, Berg TJ, et al. The effect of 8 years of strict glycaemic control on peripheral nerve function in IDDM patients: the Oslo Study. Diabetologia 1994; 37: 579 – 584.en_US
dc.identifier.citedreferenceFagerberg S‐E. Diabetic neuropathy. A clinical and histological study on the significance of vascular affections. Acta Med Scand 1959; 164: 1 – 99.en_US
dc.identifier.citedreferenceLeyden E. Die Entzundung der peripheren Nerven, deren Pathologie und Behandlung. E. S. Mittler u. Sohn: Berlin, 1888.en_US
dc.identifier.citedreferencePryce TD. On diabetic neuritis with a clinical and pathological description of three cases of diabetic psuedo‐tabes. Brain 1893; 16: 416 – 424.en_US
dc.identifier.citedreferenceEllenberg M. Diabetic neuropathic cachexia. Diabetes 1974; 23 ( 5 ): 418 – 423.en_US
dc.identifier.citedreferenceArcher AG, Watkins PJ, Thomas PK, Sharma AK, Payan J. The natural history of acute painful neuropathy in diabetes mellitus. J Neurol Neurosurg Psychiatry 1983; 46: 491 – 499.en_US
dc.identifier.citedreferenceYounger DS, Rosoklija G, Hays AP, Trojaborg W, Latov N. Diabetic peripheral neuropathy: a clinicopathologic and immunohistochemical analysis of sural nerve biopsies. Muscle Nerve 1996; 19: 722 – 727.en_US
dc.identifier.citedreferenceBrown MJ, Martin JR, Asbury AK. Painful diabetic neuropathy. A morphometric study. Arch Neurol 1976; 33: 164 – 171.en_US
dc.identifier.citedreferenceNovella SP, Inzucchi SE, Goldstein JM. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle Nerve 2001; 24: 1229 – 1231.en_US
dc.identifier.citedreferenceSingleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 2001; 24 ( 8 ): 1448 – 1453.en_US
dc.identifier.citedreferenceSingleton JR, Smith AG, Bromberg MB. Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle Nerve 2001; 24: 1225 – 1228.en_US
dc.identifier.citedreferenceSingleton JR, Smith AG, Russell JW, Feldman EL. Microvascular complications of impaired glucose tolerance. Diabetes 2003; 52: 2867 – 2873.en_US
dc.identifier.citedreferenceHoffman‐Snyder C, Smith BE, Ross MA, Hernandez J, Bosch EP. Value of the oral glucose tolerance test in the evaluation of chronic idiopathic axonal polyneuropathy. Arch Neurol 2006; 63: 1075 – 1079.en_US
dc.identifier.citedreferenceSmith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre‐diabetic neuropathy. Diabetes Care 2006; 29: 1294 – 1299.en_US
dc.identifier.citedreferenceDyck PJ, Klein CJ, Weigand SD. Does impaired glucose metabolism cause polyneuropathy? Review of previous studies and design of a prospective controlled population‐based study. Muscle Nerve 2007; 36: 536 – 541.en_US
dc.identifier.citedreferenceFranklin GM, Kahn LB, Baxter J, Marshall JA, Hamman RF. Sensory neuropathy in non‐insulin‐dependent diabetes mellitus. The San Luis Valley Diabetes Study. Am J Epidemiol 1990; 131: 633 – 643.en_US
dc.identifier.citedreferenceHughes RA, Umapathi T, Gray IA, et al. A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy. Brain 2004; 127: 1723 – 1730.en_US
dc.identifier.citedreferenceSmith AG, Ramachandran P, Tripp S, Singleton JR. Epidermal nerve innervation in impaired glucose tolerance and diabetes‐associated neuropathy. Neurology 2001; 57: 1701 – 1704.en_US
dc.identifier.citedreferenceRaff MC, Asbury AK. Ischemic mononeuropathy and mononeuropathy multiplex in diabetes mellitus. N Engl J Med 1968; 279: 17 – 22.en_US
dc.identifier.citedreferenceChokroverty S, Reyes MG, Rubino FA, Tonaki H. The syndrome of diabetic amyotrophy. Ann Neurol 1977; 2: 181 – 199.en_US
dc.identifier.citedreferenceLlewelyn JG, Thomas PK, King RHM. Epineurial microvasculitis in proximal diabetic neuropathy. J Neurol 1998; 245 ( 3 ): 159 – 165.en_US
dc.identifier.citedreferenceKelkar PM, Masood M, Parry GJ. Distinctive pathologic findings in proximal diabetic neuropathy (diabetic amyotrophy). Neurology 2000; 55 ( 1 ): 83 – 88.en_US
dc.identifier.citedreferenceAmerican Diabetes Association. American Academy of Neurology: Report and recommendations of the San Antonio conference on diabetic neuropathy. Diabetes Care 1988; 11: 592 – 597.en_US
dc.identifier.citedreferenceEngland JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: a definition for clinical research. Report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005; 64 ( 2 ): 199 – 207.en_US
dc.identifier.citedreferenceApfel SC, Schwartz S, Adornato BT, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy. A randomized controlled trial. JAMA 2000; 284: 2215 – 2221.en_US
dc.identifier.citedreferenceAd hoc panel on endpoints for diabetic neuropathy trials. Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials. J Neurol Sci 2001; 189: 3 – 6.en_US
dc.identifier.citedreferenceDyck PJ, Overland CJ, Low PA, et al. Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial. Muscle Nerve 2010; 42: 157 – 164.en_US
dc.identifier.citedreferenceDyck PJ, Kratz KM, Lehman KA, et al. The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 1991; 41: 799 – 807.en_US
dc.identifier.citedreferenceMulder DW, Lambert EH, Bastron JA, Sprague RG. The neuropathies associated with diabetes mellitus: a clinical and electromyographic study of 103 unselected diabetic patients. Neurology 1961; 11: 275 – 284.en_US
dc.identifier.citedreferenceGilliatt RW, Willison RG. Peripheral nerve conduction in diabetic neuroapthy. J Neurol Neurosurg Psychiatry 1962; 25: 11 – 18.en_US
dc.identifier.citedreferenceLaMontagne A, Buchthal F. Electrophysiological studies in diabetic neuropathy. J Neurol Neurosurg Psychiatry 1970; 33: 442 – 452.en_US
dc.identifier.citedreferenceBehse F, Buchthal F, Carlsen F. Nerve biopsy and conduction studies in diabetic neuropathy. J Neurol Neurosurg Psychiatry 1977; 40: 1072 – 1082.en_US
dc.identifier.citedreferenceKimura J, Yamada T, Stevland NP. Distal slowing of motor nerve conduction velocity in diabetic polyneuropathy. J Neurol Sci 1979; 42: 291 – 302.en_US
dc.identifier.citedreferenceDyck PJ, Litchy WJ, Lehman KA, Hokanson JL, Low PA, O'Brien PC. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of healthy subjects (RDNS‐HS). Neurology 1995; 45: 1115 – 1121.en_US
dc.identifier.citedreferenceO'Brien PC, Dyck PJ. Procedures for setting normal values. Neurology 1995; 45: 17 – 23.en_US
dc.identifier.citedreferenceDiabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995; 38 ( 6 ): 869 – 880.en_US
dc.identifier.citedreferenceAlbers JW, Herman WH, Pop‐Busui R, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care; 33: 1090 – 1096.en_US
dc.identifier.citedreferenceDyck PJ, Carter RE, Litchy WJ. Modeling nerve conduction criteria for diagnosis of diabetic polyneuropathy. Muscle Nerve 2010; (submitted for publication).en_US
dc.identifier.citedreferenceDyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 1988; 11: 21 – 32.en_US
dc.identifier.citedreferenceDyck PJB, Dyck PJ. Diabetic polyneuropathy. In Diabetic Neuropathy (2nd edn), Dyck PJ, Thomas PK (eds). W. B. Saunders Company: Philadelphia, PA, 1999; 255 – 278.en_US
dc.identifier.citedreferenceDyck PJ, Hughes RAC, O'Brien PC. Quantitating overall neuropathic symptoms, impairments, and outcomes. In Peripheral Neuropathy ( 4th edn ), Dyck PJ, Thomas PK (eds). Elsevier: Philadelphia, PA, 2005; 1031 – 1052.en_US
dc.identifier.citedreferenceDyck PJ, Daube J, O'Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986; 314: 461 – 465.en_US
dc.identifier.citedreferenceDyck PJ, Norell JE, Tritschler H, et al. Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity. Diabetes Care 2007; 30: 2619 – 2625.en_US
dc.identifier.citedreferenceDyck PJ, Turner DW, Davies JL, O'Brien PC, Dyck PJB, Rask CA; rhNGF Group. Electronic case‐report forms of symptoms and impairments of peripheral neuropathy. Can J Neurol Sci 2002; 29: 258 – 266.en_US
dc.identifier.citedreferenceThe MRC Nerve Injuries Committee (1943). Aids to the Examination of the Peripheral Nervous System. On behalf of The Guarantors of Brain (4th edn). W. B. Saunders: Philadelphia, PA, 2000.en_US
dc.identifier.citedreferenceDyck PJ, Karnes J, O'Brien P, Nukada H, Lais A, Low P. Spatial pattern of nerve fiber abnormality indicative of pathologic mechanisms. Am J Pathol 1984; 117: 225 – 238.en_US
dc.identifier.citedreferenceFeldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two‐step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994; 17: 1281 – 1289.en_US
dc.identifier.citedreferencePerkins BA, Olaleyf D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care 2001; 24: 250 – 256.en_US
dc.identifier.citedreferenceBril V, Perkins BA. Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. Diabetes Care 2002; 25: 2048 – 2052.en_US
dc.identifier.citedreferenceBril V, Tomioka S, Buchanan RA, Perkins BA. Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy. Diabet Med 2009; 26: 240 – 246.en_US
dc.identifier.citedreferenceDyck PJ, Litchy WJ, Daube JR, et al. Individual attributes versus composite scores of nerve conduction abnormality: sensitivity, reproducibility, and concordance with impairment. Muscle Nerve 2003; 27 ( 2 ): 202 – 210.en_US
dc.identifier.citedreferenceDyck PJ, O'Brien PC, Davies J, Klein CJ, Dyck PJB. Nerve tests expressed as percentiles, normal deviates, and composite scores. In Peripheral Neuropathy (4th edn ), Dyck PJ, Thomas PK (eds). Elsevier: Philadelphia, PA, 2005; 971 – 984.en_US
dc.identifier.citedreferenceDyck PJ, O'Brien PC, Litchy WJ, Harper CM, Klein CJ, Dyck PJB. Monotonicity of nerve tests in diabetes. Subclinical nerve dysfunction precedes diagnosis of polyneuropathy. Diabetes Care 2005; 28 ( 9 ): 2192 – 2200.en_US
dc.identifier.citedreferenceDyck PJ, O'Brien PC. Polyneuropathy dysfunction scores. J Neurol Neurosurg Psychiatry 2006; 77: 899 – 900.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
1226_ftp.pdf
Size:
127.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.